Assessing the severity of atopic dermatitis in clinical trials and practice
- PMID: 30217273
- DOI: 10.1016/j.clindermatol.2018.05.012
Assessing the severity of atopic dermatitis in clinical trials and practice
Abstract
There is a tremendous need for accurate and reproducible scoring systems for the grading of skin disease to further the development of research and standards of care. There are presently greater than 60 measures that have been used to assess the severity of atopic dermatitis. These assessments vary considerably with respect to content, scale, instructions, validity, and concordance. This contribution reviews the available scoring systems of atopic dermatitis signs based on their design and merit in specific settings. These scores assess lesional intensity and/or extent, symptoms, disease course, and epidermal function. Scoring atopic dermatitis, Investigator Global Assessment, and Eczema Area and Severity Index are the most commonly used assessments of atopic dermatitis signs. Eczema Area and Severity Index has emerged as the preferred outcome measure of atopic dermatitis signs for use in clinical trials. Unfortunately, Eczema Area and Severity Index can be cumbersome in clinical practice. Itch intensity (visual analog or numeric rating scales) and Patient-Oriented Eczema Measure have emerged as the preferred patient-reported outcome in clinical trials. Clinicians' gestalt global assessment of severity, Patient-Oriented Eczema Measure, and intensity of itch may be feasible for clinical practice.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Measurement properties of the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.Br J Dermatol. 2020 Nov;183(5):891-898. doi: 10.1111/bjd.18978. Epub 2020 May 10. Br J Dermatol. 2020. PMID: 32107772
-
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis.J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):10S-16S. doi: 10.1177/1203475418803628. J Cutan Med Surg. 2018. PMID: 30439297
-
Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.J Am Acad Dermatol. 2021 Sep;85(3):636-644. doi: 10.1016/j.jaad.2021.01.033. Epub 2021 Jan 20. J Am Acad Dermatol. 2021. PMID: 33484762
-
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.JAMA Dermatol. 2022 Dec 1;158(12):1429-1435. doi: 10.1001/jamadermatol.2022.4211. JAMA Dermatol. 2022. PMID: 36223090
-
Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.Curr Med Res Opin. 2021 Aug;37(8):1295-1301. doi: 10.1080/03007995.2021.1933929. Epub 2021 Jun 11. Curr Med Res Opin. 2021. PMID: 34027753
Cited by
-
Study protocol: assessing SleeP IN infants with early-onset atopic Dermatitis by Longitudinal Evaluation (The SPINDLE study).BMC Pediatr. 2022 Jun 18;22(1):352. doi: 10.1186/s12887-022-03382-3. BMC Pediatr. 2022. PMID: 35717147 Free PMC article.
-
Topical Application of a Formulation Containing Pea Proteins and Xyloglucan in Adult Patients with Atopic Dermatitis: A Double-blind, Parallel, Randomized, Placebo-controlled, Multicenter Study.J Clin Aesthet Dermatol. 2023 Jul;16(7):35-41. J Clin Aesthet Dermatol. 2023. PMID: 37560506 Free PMC article.
-
Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?Cureus. 2020 Apr 6;12(4):e7565. doi: 10.7759/cureus.7565. Cureus. 2020. PMID: 32382467 Free PMC article. Review.
-
Chronic Gut Inflammation and Dysbiosis in IBS: Unraveling Their Contribution to Atopic Dermatitis Progression.Int J Mol Sci. 2024 Feb 27;25(5):2753. doi: 10.3390/ijms25052753. Int J Mol Sci. 2024. PMID: 38473999 Free PMC article.
-
Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study.Dermatol Ther (Heidelb). 2023 Nov;13(11):2669-2679. doi: 10.1007/s13555-023-01035-6. Epub 2023 Sep 23. Dermatol Ther (Heidelb). 2023. PMID: 37740857 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials